Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
For AgomAb Therapeutics NV (AGMB), Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. each report beneficial ownership of 1,740,230 common shares, or 3.5%, as of September 30, 2026. The reports concern the same position, not three separate holdings: the American Depositary Shares are directly held by Redmile Biopharma Investments III, and each ADS represents one common share.
Redmile and Green may be deemed beneficial owners through Redmile’s role as investment manager and Green’s role as its principal; each disclaims beneficial ownership except to the extent of any pecuniary interest. The 3.5% calculation uses 49,247,975 common shares outstanding as of March 31, 2026.
Key Figures
Reported beneficial ownership:1,740,230 common shares eachOwnership percentage:3.5%Common shares outstanding:49,247,975 shares+1 more
4 metrics
Reported beneficial ownership1,740,230 common shares eachEach of the three reporting persons reports the same position as of September 30, 2026.
Ownership percentage3.5%Reported by each reporting person; based on 49,247,975 common shares outstanding as of March 31, 2026.
Common shares outstanding49,247,975 sharesAs of March 31, 2026; the basis for the reported ownership percentage.
ADS ratio1 ADS represents 1 common shareEach American Depositary Share represents one common share.
Key Terms
beneficial ownership, American Depositary Shares, shared voting power, shared dispositive power, +2 more
6 terms
beneficial ownershipregulatory
"beneficial ownership of Common Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
American Depositary Sharesfinancial
"1,740,230 American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
shared voting powerregulatory
"Shared power to vote or to direct the vote"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared power to dispose or to direct the disposition"
investment managerfinancial
"in its capacity as the investment manager"
pecuniary interestfinancial
"except to the extent of its or his pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AGMB shares do the reporting persons beneficially own?
Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. each report 1,740,230 common shares, equal to 3.5% of the class, as of September 30, 2026. Redmile Biopharma Investments III directly holds the ADSs, and each ADS represents one common share.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
AgomAb Therapeutics NV
(Name of Issuer)
Common Shares, no nominal value per share
(Title of Class of Securities)
00860C102
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Redmile Group, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,740,230.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,740,230.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,740,230.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.5 %
12
Type of Reporting Person (See Instructions)
OO, IA
Comment for Type of Reporting Person: The information in Item 4 relating to the Issuer's common shares, no nominal value per share ("Common Shares"), that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference.
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Jeremy C. Green
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,740,230.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,740,230.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,740,230.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.5 %
12
Type of Reporting Person (See Instructions)
IN, HC
Comment for Type of Reporting Person: The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference.
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Redmile Biopharma Investments III, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,740,230.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,740,230.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,740,230.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Redmile Biopharma Investments III, L.P. ("RBI III") is incorporated herein by reference.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
AgomAb Therapeutics NV
(b)
Address of issuer's principal executive offices:
Posthoflei 1/6, 2600 Antwerpen, Belgium
Item 2.
(a)
Name of person filing:
Redmile Group, LLC
Jeremy C. Green
Redmile Biopharma Investments III, L.P.
(b)
Address or principal business office or, if none, residence:
Redmile Group, LLC
900 Larkspur Landing Circle, Suite 270
Larkspur, California 94939
Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001
Redmile Biopharma Investments III, L.P.
c/o Redmile Group, LLC
900 Larkspur Landing Circle, Suite 270
Larkspur, California 94939
(c)
Citizenship:
Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom
Redmile Biopharma Investments III, L.P.: Delaware
(d)
Title of class of securities:
Common Shares, no nominal value per share
(e)
CUSIP No.:
00860C102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
There is no CUSIP number assigned to the Common Shares. CUSIP number 00860C102 has been assigned to the American Depositary Shares (ADSs) of the Issuer.
Redmile Group, LLC - 1,740,230 (1)
Jeremy C. Green - 1,740,230 (1)
Redmile Biopharma Investments III, L.P. - 1,740,230 (1)
(b)
Percent of class:
Redmile Group, LLC - 3.5% (2)
Jeremy C. Green - 3.5% (2)
Redmile Biopharma Investments III, L.P. - 3.5% (2)
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Redmile Group, LLC - 0
Jeremy C. Green - 0
Redmile Biopharma Investments III, L.P. - 0
(ii) Shared power to vote or to direct the vote:
Redmile Group, LLC - 1,740,230 (1)
Jeremy C. Green - 1,740,230 (1)
Redmile Biopharma Investments III, L.P. - 1,740,230 (1)
(iii) Sole power to dispose or to direct the disposition of:
Redmile Group, LLC - 0
Jeremy C. Green - 0
Redmile Biopharma Investments III, L.P. - 0
(iv) Shared power to dispose or to direct the disposition of:
Redmile Group, LLC - 1,740,230 (1)
Jeremy C. Green - 1,740,230 (1)
Redmile Biopharma Investments III, L.P. - 1,740,230 (1)
(1) As of September 30, 2026, each reporting person's beneficial ownership of Common Shares is comprised of 1,740,230 American Depositary Shares ("ADS"), each representing one Common Share. The ADSs are directly held by RBI III, a private investment vehicle for which Redmile is the investment manager. Redmile may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all Common Shares underlying the ADSs held by RBI III. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any.
(2) Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on April 23, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See the response to Item 4.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Redmile Group, LLC
Signature:
/s/ Jeremy C. Green
Name/Title:
Managing Member
Date:
11/16/2026
Jeremy C. Green
Signature:
/s/ Jeremy C. Green
Name/Title:
Jeremy C. Green
Date:
11/16/2026
Redmile Biopharma Investments III, L.P.
Signature:
/s/ Jeremy C. Green
Name/Title:
Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.